(-0.04%) 5 306.00 points
(-0.01%) 40 139 points
(-0.06%) 18 492 points
(1.14%) $82.28
(-1.28%) $1.696
(1.87%) $2 231.50
(0.00%) $24.75
(0.14%) $910.95
(0.37%) $0.927
(0.58%) $10.83
(0.15%) $0.792
(-0.25%) $92.21
4 days till quarter result
(bmo 2024-04-01)
Expected move: +/- 0.00%
Live Chart Being Loaded With Signals
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV...
Stats | |
---|---|
Today's Volume | 3 292.00 |
Average Volume | 35 144.00 |
Market Cap | 849.08M |
EPS | €0 ( 2024-03-14 ) |
Next earnings date | ( €0 ) 2024-04-01 |
Last Dividend | €0 ( N/A ) |
Next Dividend | €0 ( N/A ) |
P/E | -5.56 |
ATR14 | €0.0640 (0.47%) |
Volume Correlation
Abivax SA Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Abivax SA Correlation - Currency/Commodity
Abivax SA Financials
Annual | 2022 |
Revenue: | €0 |
Gross Profit: | €-71 000.00 (0.00 %) |
EPS: | €-3.13 |
Q2 | 2023 |
Revenue: | €2.25M |
Gross Profit: | €2.25M (100.00 %) |
EPS: | €-1.450 |
Q4 | 2022 |
Revenue: | €0 |
Gross Profit: | €-32 000.00 (0.00 %) |
EPS: | €-1.810 |
Q3 | 2022 |
Revenue: | €0 |
Gross Profit: | €-17 461.00 (0.00 %) |
EPS: | €-0.900 |
Financial Reports:
No articles found.
Abivax SA
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators